Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > The pressure is on for Big Pharma...& Onc.

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Dec 04, 2022 7:02am

214 Views

Post# 35149228

RE:RE:RE:The pressure is on for Big Pharma...& Onc.

Interesting thought though. For the FDA Accelerated Approval Program a surrogate endpoint is required. I am assuming (perhaps incorrectly) that a biomarker might qualify. PDAC certainly has an unmet need. With GOBLET maturing, and signs that we have a biomarker, I do not see why asking for Accelerated Approval is not in the cards.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario